CONTOUR DIABETES app (US)
For adults managing diabetes who use CONTOUR connected blood glucose meters.
Overview · Full Intel report in progress
CONTOUR DIABETES app (US) is an established medical app that is completely free. With a 3.3/5 rating from 4.4K reviews, it shows polarized user reception.
What is CONTOUR DIABETES app (US)?
Current Momentum
v3.5 · 20mo ago
ZombieLast updated 617d ago. 5 versions tracked.
Competition
Rivals identification in progress
7-Day Rank Pulse 🇺🇸
MedicalNo ranking data
Rating Pulse 🇺🇸
What makes this app unique?
What Does It Look Like?
What Are The Key Features?
Connects with CONTOUR blood glucose meters to automatically import monitoring data.
Presents blood glucose results in a personalized, easy-to-review format.
Allows users to log daily activities to better understand their effect on glucose levels.
How much does it cost?
Who Built It?
Portfolio
13
Apps
What other apps does Ascensia Diabetes Care US make?
CONTOUR DIABETES app (DK)
CONTOUR DIABETES app (LK)
CONTOUR DIABETES app (LT)
CONTOUR DIABETES app (MY)
CONTOUR DIABETES app (HK)
CONTOUR DIABETES app
Explore the full Ascensia Diabetes Care US report
Portfolio breakdown, audience, momentum, and every app published by Ascensia Diabetes Care US.
Analysis in progress, available soon
What do users think recently?
Analysis in progress, available soon
View the full user-sentiment analysis
Mood gauge, ratings & review-volume history, every praise / complaint / request, and sentiment over time.
Analysis in progress, available soon
What is the competitive landscape for CONTOUR DIABETES app (US)?
How's The Medical Market?
How does it evolve in the Medical market?
Rank progression
1 active ranking tracked — 30-day window
Strategic analysis coming soon
SWOT, key takeaways & outlook
The outtake for CONTOUR DIABETES app (US)
Key Takeaways
While marketed as a tool for diabetes management, recent user feedback highlights significant technical challenges regarding data synchronization and app stability.
Where Is It Heading?
Trend analysis
Available very soon